STOCK TITAN

CareDx (CDNA) insider Peter Maag files to sell 7,000 shares after large prior sales

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

PETER MAAG filed to sell common stock of CDNA. The notice lists a proposed sale of 7,000 shares through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $317,112.60, against 51,734,223 shares outstanding as of the filing. It also details multiple common stock sales over the prior three months, including blocks of 75,653, 46,963, and 27,332 shares, each with corresponding dollar amounts.

Positive

  • None.

Negative

  • None.
Proposed shares to be sold 7,000 shares Planned common stock sale listed through Morgan Stanley Smith Barney LLC Executive Financial Services
Aggregate market value of proposed sale $317,112.60 Value associated with the 7,000-share proposed common stock sale
Shares outstanding 51,734,223 shares Outstanding common stock referenced for the issuer
Recent block sale 75,653 shares for $3,576,851.19 Common stock sale dated 08/04/2026 by Peter Maag
Recent block sale 46,963 shares for $2,178,945.34 Common stock sale dated 08/05/2026 by Peter Maag
Recent block sale 27,332 shares for $1,252,491.63 Common stock sale dated 08/07/2026 by Peter Maag
Restricted Stock financial
"Common | 02/03/2024 | Restricted Stock | Issuer"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Executive Financial Services financial
"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"
Securities To Be Sold financial
"144: Securities To Be Sold"
Securities Sold During The Past 3 Months financial
"144: Securities Sold During The Past 3 Months"

FAQ

What does the CDNA Form 144 filing by Peter Maag disclose?

The filing discloses a planned sale of 7,000 CDNA common shares with an aggregate market value of $317,112.60, plus a history of several sizeable common stock sales over the past three months.

How many CDNA shares is Peter Maag currently planning to sell under this notice?

The notice lists a proposed sale of 7,000 CDNA common shares. These shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with the filing citing an aggregate market value of $317,112.60 for this block.

What is the outstanding share count of CDNA referenced in this Form 144?

The document cites 51,734,223 CDNA common shares outstanding. This figure provides context for the relative size of the 7,000-share proposed sale disclosed in the notice.

Which broker is listed for the proposed CDNA stock sale in this filing?

The proposed 7,000-share CDNA sale is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004, with trading noted on NASDAQ.

What prior CDNA stock sales by Peter Maag are reported in the last three months?

The filing reports several CDNA common stock sales, including 75,653 shares for $3,576,851.19, 46,963 shares for $2,178,945.34, and 27,332 shares for $1,252,491.63, along with additional 6,902–7,000 share transactions.

On which market is the CDNA common stock referenced in this Form 144 traded?

The common stock referenced in the notice is traded on NASDAQ. The filing associates the proposed 7,000-share sale and the issuer’s 51,734,223 outstanding shares with this trading venue.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature